001483897 000__ 07050cam\\22005417a\4500
001483897 001__ 1483897
001483897 003__ OCoLC
001483897 005__ 20240117003306.0
001483897 006__ m\\\\\o\\d\\\\\\\\
001483897 007__ cr\un\nnnunnun
001483897 008__ 231104s2023\\\\sz\\\\\\o\\\\\000\0\eng\d
001483897 019__ $$a1407277578
001483897 020__ $$a9783031409011$$q(electronic bk.)
001483897 020__ $$a3031409019$$q(electronic bk.)
001483897 020__ $$z3031409000
001483897 020__ $$z9783031409004
001483897 0247_ $$a10.1007/978-3-031-40901-1$$2doi
001483897 035__ $$aSP(OCoLC)1407313541
001483897 040__ $$aEBLCP$$beng$$cEBLCP$$dYDX$$dGW5XE$$dYDX$$dOCLCO
001483897 049__ $$aISEA
001483897 050_4 $$aRC280.K5$$bI584 2023
001483897 08204 $$a616.99/46106$$223/eng/20231116
001483897 24500 $$aIntegrating multidisciplinary treatment for advanced renal cell carcinoma /$$cRana R. McKay, Eric A. Singer, editors.
001483897 260__ $$aCham :$$bSpringer,$$c2023.
001483897 300__ $$a1 online resource (418 p.)
001483897 500__ $$aLaparoscopic and Robotic Approaches: Radical Nephrectomy
001483897 5050_ $$aIntro -- Contents -- Part I: Localized Disease -- 1: Prognostic Factors for Localized Renal Cell Carcinoma -- Introduction -- Clinical -- Anatomic -- Histopathologic -- Molecular -- Integrated Predictive Tools -- Conclusion -- References -- 2: Active Surveillance of Patients with Clinically Localized Small Renal Masses -- Introduction -- Active Surveillance Definition -- Small Renal Mass (SRM) Indolence -- Trends in Active Surveillance Utilization -- Selection of Patients for Active Surveillance -- Tumor Factors -- Patient Factors -- Active Surveillance Imaging and Monitoring
001483897 5058_ $$aRole of Renal Mass Biopsy (RMB) in Active Surveillance -- Triggers for Delayed Intervention (DI) During Active Surveillance -- Tumor Factors -- Major "GLASS" PCI -- Minor "GLASS" PCI -- Patient Factors -- Research Support for Active Surveillance -- Systematic Reviews -- Active Surveillance Series with Prospective Management Pathways -- Summary of Consensus Guidelines -- American Urological Association (AUA) Guidelines -- European Association of Urology (EAU) Guidelines -- Canadian Urology Association (CUA) Guidelines -- National Comprehensive Cancer Network (NCCN) Guidelines
001483897 5058_ $$aAmerican Society of Clinical Oncology (ASCO) Guidelines -- European Society of Medical Oncology (ESMO) Guidelines -- Conclusion -- References -- 3: Partial Nephrectomy in the  Treatment of RCC -- Historical Background -- Controversies -- Indication for Partial Nephrectomy -- Patient Selection -- Describing the Surgical Complexity of Tumors -- Surgical Techniques -- Transperitoneal Vs. Retroperitoneal -- Ischemia -- Standard Partial Vs. Enucleation -- Renorrhaphy -- Hemostatic Agents -- Functional Outcomes: Preserving Renal Parenchyma and Renal Function -- Oncologic Outcomes
001483897 5058_ $$aSurveillance Following Partial Nephrectomy -- Additional Considerations: Hereditary, Multifocal, and Advanced Disease -- Partial Nephrectomy on a Solitary Kidney -- Multifocal and Repeat Partial Nephrectomy -- Partial Nephrectomy in Management of Hereditary RCC Syndromes -- Partial Nephrectomy in pT3a RCC -- Partial Nephrectomy in Metastatic Disease -- Conclusions and Future Directions -- References -- 4: Ablative Options for Renal Cell Carcinoma -- Introduction -- Technique Considerations -- Cryoablation -- Radiofrequency Ablation -- Microwave Ablation
001483897 5058_ $$aEvaluation of Post-Ablation Treatment Success and Surveillance -- Role of Biopsy -- Oncologic Outcomes and Surveillance Regimens -- Complications of TA -- Radiation Therapy -- Conclusions -- References -- 5: Radical Nephrectomy for Renal Cell Carcinoma -- Introduction -- Techniques -- Open Surgical Approaches: Radical Nephrectomy -- Anterior Approaches -- Midline Transperitoneal Incision -- Chevron Incision -- Subcostal Incision -- Flank Approaches -- Eleventh or Twelfth Rib Supracostal and Transcostal Incision -- Thoracoabdominal Incision
001483897 506__ $$aAccess limited to authorized users.
001483897 520__ $$aThe field of kidney cancer has dramatically evolved over the past several years due to notable advances. Most importantly, systemic treatment options have expanded to include combination regimens for advanced disease and expansion of treatment options in the adjuvant setting. Additionally, surgical management has evolved towards nephron-sparing and minimally invasive approaches for treatment of localized disease; the role of surgery and focal therapy are changing for patients with advanced disease. While kidney cancer is a common malignancy in both men and women worldwide, mortality has improved over time given advancements in modern oncology. This book provides a comprehensive, state-of-the art review of the field, and serves as a valuable resource for clinicians, surgeons and researchers with an interest in kidney cancer. The book reviews new data about systemic treatment options for patients with advanced disease including strategies in the treatment nave and post frontline setting. It covers new data regarding perioperative and adjuvant treatments for patients with localized disease and will highlight novel targets and treatments under development. Integration of surgery and systemic therapy through cytoreductive and consolidative approaches has yielded provocative data that promises to further advance the field, and major advances in this domain will also be discussed. Additionally, the book discusses the evolving role of alternative focal approaches including radiation therapy for patients with advanced disease. This text serves as a very useful resource for physicians and researchers dealing with and interested in this challenging malignancy. Specifically, urologists, medical oncologists, radiation oncologists, basic science and translational researchers with interest in RCC, fellows in urologic oncology, upper level residents training in urology and medical oncology, and pharmaceutical partners interested in RCC will benefit most significantly. Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma will provide a concise yet comprehensive summary of strategies for sequencing therapies that will help guide patient care and stimulate investigative efforts.
001483897 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed November 16, 2023).
001483897 650_0 $$aKidneys$$xCancer$$xTreatment.
001483897 650_6 $$aReins$$xCancer$$xTraitement.
001483897 655_0 $$aElectronic books.
001483897 7001_ $$aMcKay, Rana R.
001483897 7001_ $$aSinger, Eric A.
001483897 77608 $$iPrint version:$$aMcKay, Rana R.$$tIntegrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma$$dCham : Springer International Publishing AG,c2023$$z9783031409004
001483897 852__ $$bebk
001483897 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-40901-1$$zOnline Access$$91397441.1
001483897 909CO $$ooai:library.usi.edu:1483897$$pGLOBAL_SET
001483897 980__ $$aBIB
001483897 980__ $$aEBOOK
001483897 982__ $$aEbook
001483897 983__ $$aOnline
001483897 994__ $$a92$$bISE